by Claire | Oct 23, 2022 | Uncategorized
DIADEM RECEIVES CE-IVD CERTIFICATION TO MARKET ITS ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE IN EUROPE —First Approved Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance—...
by Claire | Oct 23, 2022 | Uncategorized
PRESENTATION AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE MEETING HIGHLIGHTS HOW DIADEM’S ALZOSURE® PREDICT CAN ENABLE AD CLINICAL TRIALS AND SCREENING FOR EARLY DETECTION OF AD —Longitudinal Analyses Show AlzoSure® Predict Identifies Individuals Who Will Progress to...
by Claire | Oct 23, 2022 | Uncategorized
FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO DIADEM’S ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE —First Prognostic Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance— ...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS DATA AT AD/PD™ 2022 INTERNATIONAL CONFERENCE DEMONSTRATING ITS NEW ALZOSURE® CONFIRM BLOOD TEST HAS THE POTENTIAL TO ACCURATELY DIAGNOSE ALZHEIMER’S DISEASE —Have Identified Specific Post Translational Modifications of a Conformational Variant of p53...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF PEER-REVIEWED ARTICLE DESCRIBING HOW POST-TRANSLATIONAL MODIFICATIONS OF P53 VARIANTS MAY CONTRIBUTE TO DEVELOPMENT OF ALZHEIMER’S DISEASE —Post-Translational Modifications of Conformational Variants of p53 Appear to Impact Pathogenesis...
